CA14161Y2006 - Common Stock
CARDIOL THERAPEUTICS INC-A
NASDAQ:CRDL (10/9/2024, 8:00:00 PM)
After market: 1.82 -0.01 (-0.55%)1.83
-0.13 (-6.63%)
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company is headquartered in Oakville, Ontario. The company went IPO on 2018-12-20. The firm is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. The company is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. The company is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. The company has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
CARDIOL THERAPEUTICS INC-A
602-2265 Upper Middle Road East
Oakville ONTARIO
P: 12899100850
Employees: 17
Website: https://www.cardiolrx.com/
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Here you can normally see the latest stock twits on CRDL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: